CLINICAL TRIALS PROFILE FOR GLUCOTROL

All Clinical Trials for GLUCOTROL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00032474 ↗	Ginkgo Biloba Extract and the Insulin Resistance Syndrome	Completed	National Center for Complementary and Integrative Health (NCCIH)	Phase 1/Phase 2	2001-12-01	The purpose of this study is to examine whether the ingestion of the herbal dietary supplement Ginkgo biloba extract has any effect on the efficacy of three classes of diabetic medications - (Glucotrol, Glucophage and Actose). Additionally, the study will examine the effect of Ginkgo biloba extract on pancreatic insulin production in non-diabetic subjects between the ages of 20 and 75 years old.
NCT00350779 ↗	Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-06-12	A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy.
NCT00509236 ↗	Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2007-10-19	The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control.
NCT00509262 ↗	Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2007-10-09	The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in participants with moderate or severe renal insufficiency.
NCT00550329 ↗	Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets	Completed	Pfizer		2007-10-01	The objective of this study is to determine the bioequivalence of Glipizide GITS (Glucotrol XL) 2.5 mg tablets manufactured at the Brooklyn, New York facility versus tablets manufactured at the facility in Barceloneta, Puerto Rico.
NCT00660907 ↗	Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients	Completed	Bristol-Myers Squibb	Phase 3	2008-03-01	This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.

Clinical Trial Conditions for GLUCOTROL

Condition Name

Condition Name for GLUCOTROL
Intervention	Trials
Type 2 Diabetes Mellitus	7
Diabetes Mellitus, Type 2	2
Type 2 Diabetes	2
Impaired Glucose Tolerance	1

Condition MeSH

Condition MeSH for GLUCOTROL
Intervention	Trials
Diabetes Mellitus	12
Diabetes Mellitus, Type 2	11
Renal Insufficiency, Chronic	3
Renal Insufficiency	2

Clinical Trial Locations for GLUCOTROL

Trials by Country

Trials by Country for GLUCOTROL
Location	Trials
United States	62
India	17
Mexico	11
Italy	10
Hungary	9

Trials by US State

Trials by US State for GLUCOTROL
Location	Trials
Texas	5
Utah	3
Pennsylvania	3
Nebraska	3
California	3

Clinical Trial Progress for GLUCOTROL

Clinical Trial Phase

Clinical Trial Phase for GLUCOTROL
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	8
Phase 2	2

Clinical Trial Status

Clinical Trial Status for GLUCOTROL
Clinical Trial Phase	Trials
Completed	14
Recruiting	1

Clinical Trial Sponsors for GLUCOTROL

Sponsor Name

Sponsor Name for GLUCOTROL
Sponsor	Trials
Merck Sharp & Dohme Corp.	5
Takeda	2
AstraZeneca	1

Sponsor Type

Sponsor Type for GLUCOTROL
Sponsor	Trials
Industry	12
Other	4
NIH	1

GLUCOTROL Market Analysis and Financial Projection

GLUCOTROL: Clinical Trials, Market Analysis, and Projections

Introduction to GLUCOTROL

GLUCOTROL, also known as glipizide, is an oral antidiabetic medication used in the management of type 2 diabetes mellitus (T2DM). It belongs to the class of sulfonylureas, which work by stimulating the release of insulin from the pancreatic beta cells. Here, we will delve into the current clinical trials, market analysis, and projections for GLUCOTROL.

Clinical Trials and Efficacy

While GLUCOTROL itself is an established medication, the landscape of diabetes treatment is continuously evolving with new therapies and treatments being developed. Here’s a look at the broader context and some relevant clinical trials in the diabetes management field.

GLP-1R Agonists: A Comparative Context

Recent clinical trials have focused on newer classes of drugs such as GLP-1 receptor agonists (GLP-1RAs), which have shown promising results in managing T2DM and obesity. For example, Pfizer's danuglipron, an oral GLP-1RA, has been in late-stage clinical development. A Phase 2b trial conducted from July 2020 to July 2021 investigated the efficacy, safety, and tolerability of danuglipron in adults with T2DM. This trial highlighted the potential of GLP-1RAs as a future treatment option, though it does not directly involve GLUCOTROL[4].

Market Analysis

Current Market Size and Growth

The global market for diabetes treatments, including medications like GLUCOTROL, has been growing steadily. The glucose market size, which includes various diabetes treatments, is projected to expand from $51.55 billion in 2023 to $54.94 billion in 2024, with a compound annual growth rate (CAGR) of 6.6%[2].

Drivers of Market Growth

Several factors are driving this growth:

• Increased Prevalence of Diabetes: The global diabetes epidemic continues to grow, driving the demand for effective antidiabetic medications.
• Aging Population: An aging population contributes to the increased incidence of T2DM.
• Changes in Lifestyles and Dietary Habits: Modern lifestyles and dietary habits have led to a higher risk of developing diabetes.
• Government Initiatives and Healthcare Infrastructure: Improved healthcare infrastructure and government initiatives have enhanced access to diabetes treatments[2].

Competitive Landscape

The market for T2DM treatments is highly competitive, with several pharmaceutical companies involved. GLUCOTROL, being a well-established medication, faces competition from newer classes of drugs like GLP-1RAs. Companies such as Eli Lilly, AstraZeneca, Sanofi, and Boehringer Ingelheim are key players in the GLP-1RA market, which is expected to grow at a CAGR of 14.9% to reach $125 billion by 2033[3].

Projections and Future Outlook

GLUCOTROL's Position in the Market

Despite the emergence of new therapies, GLUCOTROL remains a vital component of diabetes management due to its established efficacy and safety profile. Here are some key projections:

Continued Demand

• The demand for GLUCOTROL is expected to remain steady due to its role in personalized and patient-centric diabetes treatment plans. Healthcare providers often customize treatment plans, and GLUCOTROL is frequently included as part of a comprehensive approach to glycemic control[5].

Market Trends

• The trend toward personalized medicine and the integration of digital health solutions will continue to influence the market. GLUCOTROL, as a part of this multifaceted approach, will likely see sustained demand[5].

Competitive Pressure

• The growing market for GLP-1RAs and other newer therapies may pose competitive pressure on traditional medications like GLUCOTROL. However, its established presence and cost-effectiveness are likely to maintain its market share[3].

Key Takeaways

• Established Efficacy: GLUCOTROL has a well-documented efficacy and safety profile in managing T2DM.
• Market Growth: The global diabetes treatment market is growing, driven by an increasing prevalence of diabetes, an aging population, and changes in lifestyles.
• Competitive Landscape: The market is competitive, with newer classes of drugs like GLP-1RAs gaining traction.
• Future Outlook: GLUCOTROL is expected to maintain its position due to its role in personalized diabetes treatment plans and its cost-effectiveness.

FAQs

What is GLUCOTROL used for?

GLUCOTROL, or glipizide, is used in the management of type 2 diabetes mellitus (T2DM) to help control blood sugar levels.

How does GLUCOTROL work?

GLUCOTROL works by stimulating the release of insulin from the pancreatic beta cells, thereby helping to lower blood sugar levels.

What are the key drivers of the diabetes treatment market?

The key drivers include the increasing prevalence of diabetes, an aging population, changes in lifestyles and dietary habits, and improved healthcare infrastructure.

How does the emergence of GLP-1RAs affect GLUCOTROL?

The emergence of GLP-1RAs may pose competitive pressure, but GLUCOTROL's established efficacy, safety profile, and cost-effectiveness are likely to maintain its market share.

What is the projected growth of the diabetes treatment market?

The glucose market size is expected to grow from $51.55 billion in 2023 to $70.25 billion by 2028 at a CAGR of 6.3%[2].

Sources

1. Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus - Pfizer Inc.
2. Glucose Global Market Report 2024: Trending Dynamics, Forecasts, and Market Impact Analysis - The Business Research Company
3. Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: Major Market Analysis - GlobalData
4. Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron - JAMA Network Open
5. Glipizide (Glucotrol) Manufacturing Plant Project Report 2024 - IMARC Group